Skip to Content
Merck
CN

SML2906

Sigma-Aldrich

ERGi-USU

≥98% (HPLC)

Synonym(s):

1-[2-(2-Thiazolyl)diazenyl]-2-naphthalenol, 1-[2-Thiazolylazo]-2-naphthol, NSC139021, TAN

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C13H9N3OS
CAS Number:
Molecular Weight:
255.30
UNSPSC Code:
12352200
NACRES:
NA.77
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

faint brown to dark red

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

[s]1c(ncc1)N=Nc2c3c(ccc2O)cccc3

InChI

1S/C13H9N3OS/c17-11-6-5-9-3-1-2-4-10(9)12(11)15-16-13-14-7-8-18-13/h1-8,17H

InChI key

IOMXCGDXEUDZAK-UHFFFAOYSA-N

Biochem/physiol Actions

ERGi-USU is a selective and potent inhibitor of growth of ERG positive cancer cell lines, while spearing normal prostate or endothelial cells. It potently inhibits growth of ERG positive VCaP xenografts in mice. ERGi-USU is a potent and selective ligand of the ribosomal atypical kinase RIOK2 (right open reading frame (RIO) kinase 2) that induces ribosomal stress.
potent and selective ligand of the ribosomal atypical kinase RIOK2; inhibitor of growth of ERG positive cancer cell lines

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ahmed A Mohamed et al.
Cancer research, 78(13), 3659-3671 (2018-05-02)
Oncogenic activation of the ETS-related gene (ERG) by recurrent gene fusions (predominantly TMPRSS2-ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer. In this study, we screened small-molecule libraries for inhibition of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service